Requirements for a minimum standard of care for phenylketonuria: the patients' perspective

Tobias S Hagedorn1, Paul van Berkel, Gregor Hammerschmidt

  • 1European Society for Phenylketonuria and Allied Disorders (E,S,PKU), Melsele, Belgium. tobias-hagedorn@t-online.de.

Insights

Phenylketonuria (PKU) is an inherited disorder requiring early dietary management. This article proposes pan-European standards for consistent PKU screening, treatment, and monitoring to ensure equal access to care for all patients.

Area of Science:

  • Metabolic Disorders
  • Genetics
  • Public Health

Background:

  • Phenylketonuria (PKU) is an inherited metabolic disorder affecting approximately 1 in 10,000 European births.
  • Effective management relies on early and continuous dietary modification to prevent severe neurological damage.
  • Current PKU care exhibits significant inconsistency across Europe, with fragmented guidelines and sporadic implementation.

Purpose of the Study:

  • To present the first pan-European patient/carer perspective on optimal PKU care.
  • To propose recommendations for a minimum standard of care for PKU.
  • To inform the development of new pan-European guidelines for PKU management.

Main Methods:

  • Compilation of patient and carer perspectives from the European Society for Phenylketonuria and Allied Disorders (E.S.PKU).
  • Formulation of recommendations for standardized screening, treatment, and monitoring protocols.
  • Emphasis on the establishment of multidisciplinary Centres of Expertise.

Main Results:

  • Advocacy for standardized screening protocols and interpretation of results across Europe.
  • Requirement for experienced Centres of Expertise to ensure comprehensive multidisciplinary care.
  • Highlighting the critical need for intensive management in women of childbearing age due to fetal risks.

Conclusions:

  • Implementation of new best practice standards is crucial for equal access to PKU screening, treatment, and monitoring throughout Europe.
  • Reimbursement for all treatment aspects is essential for uniform access to evidence-based care.
  • PKU healthcare professionals are urged to lead guideline development while advocating for patients and families.

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
1.1K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
679
Nursing Ethical Principles II01:27

Nursing Ethical Principles II

Ethical principles are essential in guiding nurses to fulfill their responsibilities, focusing on the quality of nursing care and decision-making. These principles, including autonomy, beneficence, non-maleficence, justice, and fidelity, shape the ethical framework within healthcare settings.
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
2.4K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
408